<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>生物科技股票在延长交易中出现剧烈波动，多个股票在常规交易大幅下跌后反弹。新的临床数据、FDA 的指定和融资公告推动了整个行业的动能，突显出投资者密切关注的催化剂。</p>
<p>Stoke Therapeutics, Inc. (STOK) 在盘后交易中上涨至 $33.95 (+11.42%)，而常规交易收于 $30.47 (-7.67%)。此次反弹是在 2025 年 AES 年会上与 Biogen (BIIB) 的数据显示，支持 zorevunersen 在 Dravet 综合症中的潜力。</p>
<p>Alpha Tau Medical Ltd. (DRTS) 在盘后交易中股价大幅上涨。该股上涨至 $5.30，涨幅为 25.26%，即 $1.07。在常规市场收盘时（东部时间下午 4:00），股价为 $4.23，上涨 34 美分或 8.74%。该公司宣布首位患者已在其针对复发性多形性胶质母细胞瘤（GBM）的试点研究中接受治疗，使用 Alpha DaRT 技术。</p>
<p>Absci Corp. (ABSI) 在盘后交易中上涨至 $3.65 (+3.69%)，在常规交易收于 $3.52 (+2.03%)。周二没有新的消息，但在 12 月 4 日，该公司宣布在其 ABS-201 的 1/2a 阶段 HEADLINE 研究中进行了首位志愿者的给药。</p>
<p>COMPASS Pathways plc (CMPS) 在盘后交易中上涨至 $6.64 (+4.40%)，而常规交易收于 $6.36 (+0.95%)。该公司宣布计划于 2026 年 1 月 7 日举办网络研讨会，讨论 TRD 的商业准备和 PTSD 的临床试验计划。</p>
<p>Senti Biosciences, Inc. (SNTI) 在盘后交易中上涨至 $1.60 (+3.92%)，尽管常规交易大幅下跌至 $1.54 (-35.56%)。此次反弹是由于 FDA 授予 SENTI-202 其针对 AML 和其他血液恶性肿瘤的研究性 CAR-NK 细胞疗法的 RMAT 指定。</p>
<p>TuHURA Biosciences, Inc. (HURA) 在盘后交易中小幅上涨至 $1.18 (+0.85%)，此前在收盘时大幅下跌至 $1.17 (-40.91%)。该公司宣布以每股 $1.65 的价格直接发行 940 万股股票和认股权证。</p>
<p>Maravai LifeSciences Holdings, Inc. (MRVI) 在盘后交易中上涨至 $3.86 (+7.32%)，而常规交易收于 $3.69 (+2.22%)。周二没有报告公司特定的新闻。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

DRTS

CMPS

STOK

<p>生物科技股票在常规交易时段大幅下跌后，在盘后交易中反弹。Stoke Therapeutics、Alpha Tau Medical 和 Compass Pathways 领涨，得益于临床数据、FDA 认证和融资公告。Stoke Therapeutics 上涨 11.42%，Alpha Tau Medical 激增 25.26%，Compass Pathways 上涨 4.40%。其他值得注意的股票包括 Absci Corp、Senti Biosciences、TuHURA Biosciences 和 Maravai LifeSciences Holdings</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements drove momentum across the sector, highlighting catalysts that investors are watching closely.</p>
<div class="lb-trans"><p>生物科技股票在延长交易中出现剧烈波动，多个股票在常规交易大幅下跌后反弹。新的临床数据、FDA 的指定和融资公告推动了整个行业的动能，突显出投资者密切关注的催化剂。</p>
</div><p>Stoke Therapeutics, Inc. (STOK) traded up to $33.95 (+11.42%) post-market hours, after closing at $30.47 (-7.67%). The rebound followed data presentations with Biogen (BIIB) at the 2025 AES Annual Meeting, supporting the potential of zorevunersen for Dravet syndrome.</p>
<div class="lb-trans"><p>Stoke Therapeutics, Inc. (STOK) 在盘后交易中上涨至 $33.95 (+11.42%)，而常规交易收于 $30.47 (-7.67%)。此次反弹是在 2025 年 AES 年会上与 Biogen (BIIB) 的数据显示，支持 zorevunersen 在 Dravet 综合症中的潜力。</p>
</div><p>Alpha Tau Medical Ltd. (DRTS) saw a sharp surge in its share price during after-hours trading. The stock climbed to $5.30, marking a gain of 25.26%, or $1.07. At the regular market close, recorded at 4:00 PM EST, the shares settled at $4.23, up 34 cents or 8.74%. The company announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.</p>
<div class="lb-trans"><p>Alpha Tau Medical Ltd. (DRTS) 在盘后交易中股价大幅上涨。该股上涨至 $5.30，涨幅为 25.26%，即 $1.07。在常规市场收盘时（东部时间下午 4:00），股价为 $4.23，上涨 34 美分或 8.74%。该公司宣布首位患者已在其针对复发性多形性胶质母细胞瘤（GBM）的试点研究中接受治疗，使用 Alpha DaRT 技术。</p>
</div><p>Absci Corp. (ABSI) rose to $3.65 (+3.69%) after hours, building on a close of $3.52 (+2.03%). No fresh news on Tuesday, but on December 4 the company announced first volunteer dosing in its Phase 1/2a HEADLINE study of ABS-201, an investigational anti-PRLR antibody.</p>
<div class="lb-trans"><p>Absci Corp. (ABSI) 在盘后交易中上涨至 $3.65 (+3.69%)，在常规交易收于 $3.52 (+2.03%)。周二没有新的消息，但在 12 月 4 日，该公司宣布在其 ABS-201 的 1/2a 阶段 HEADLINE 研究中进行了首位志愿者的给药。</p>
</div><p>COMPASS Pathways plc (CMPS) climbed to $6.64 (+4.40%) after hours, after finishing at $6.36 (+0.95%). The company announced plans to host a webinar on Jan. 7, 2026, covering commercial preparations for TRD and clinical trial plans for PTSD.</p>
<div class="lb-trans"><p>COMPASS Pathways plc (CMPS) 在盘后交易中上涨至 $6.64 (+4.40%)，而常规交易收于 $6.36 (+0.95%)。该公司宣布计划于 2026 年 1 月 7 日举办网络研讨会，讨论 TRD 的商业准备和 PTSD 的临床试验计划。</p>
</div><p>Senti Biosciences, Inc. (SNTI) surged to $1.60 (+3.92%) after hours, despite closing sharply lower at $1.54 (-35.56%). The rally was driven by news that the FDA granted RMAT designation to SENTI-202, its investigational CAR-NK cell therapy for AML and other hematologic malignancies.</p>
<div class="lb-trans"><p>Senti Biosciences, Inc. (SNTI) 在盘后交易中上涨至 $1.60 (+3.92%)，尽管常规交易大幅下跌至 $1.54 (-35.56%)。此次反弹是由于 FDA 授予 SENTI-202 其针对 AML 和其他血液恶性肿瘤的研究性 CAR-NK 细胞疗法的 RMAT 指定。</p>
</div><p>TuHURA Biosciences, Inc. (HURA) edged up to $1.18 (+0.85%) after hours, following a steep decline to $1.17 (-40.91%) at the close. The company announced a registered direct offering of 9.4 million shares and warrants, priced at $1.65 per share.</p>
<div class="lb-trans"><p>TuHURA Biosciences, Inc. (HURA) 在盘后交易中小幅上涨至 $1.18 (+0.85%)，此前在收盘时大幅下跌至 $1.17 (-40.91%)。该公司宣布以每股 $1.65 的价格直接发行 940 万股股票和认股权证。</p>
</div><p>Maravai LifeSciences Holdings, Inc. (MRVI) advanced to $3.86 (+7.32%) after hours, after closing at $3.69 (+2.22%). No company-specific news was reported on Tuesday.</p>
<div class="lb-trans"><p>Maravai LifeSciences Holdings, Inc. (MRVI) 在盘后交易中上涨至 $3.86 (+7.32%)，而常规交易收于 $3.69 (+2.22%)。周二没有报告公司特定的新闻。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

盘后股价上涨：Stoke Therapeutics、Alpha Tau Medical、Compass Pathways 领涨生物科技股